What CAR-T cell therapy is
CAR-T (chimeric antigen receptor T-cell) therapy is an advanced cell therapy developed for specific types of blood cancer. In China it is delivered in regulated centers, under strict clinical review, and only for patients whose disease and overall condition meet the eligibility criteria set by the treating team.
Why medical evaluation comes first
Responses to CAR-T vary significantly between individuals and depend on disease type, prior treatment and overall health; outcomes cannot be promised in advance. Any decision should follow a documented evaluation by a qualified oncology team — not online claims. MedBridge arranges records review and a specialist consultation in a regulated center, with a written assessment of eligibility, options and risks in your language.
How MedBridge coordinates the consultation
Submit medical records, imaging and pathology; the team matches you to an appropriate oncology center within 1-2 working days; a documented consultation (in person or by video) follows with 12-language interpretation. 20+ international insurers support direct billing where applicable. WhatsApp (+86 138 1783 1623) or email [email protected].